[opensourcepharma] Recent Items Relevant to Open Source Pharma
mattoddchem at gmail.com
Wed Mar 18 03:30:28 UTC 2015
A collection of recent items that might be of interest to you all that have
built up in my browsers during the recent grant-writing bonanza in
1) Call from the NIH on "Big Data to Knowledge (BD2K) Advancing Biomedical
Science Using Crowdsourcing and Interactive Digital Media"
2) The NIH screen for known drugs showing promise vs Ebola, featuring John
3) Whole issue of Chem Rev on neglected disease drug discovery
4) "The Drugs for Neglected Diseases initiative (DNDi) has been awarded US$
10 million by the United States Agency for International Development
(USAID) to develop new treatments for onchocerciasis (river blindness) and
lymphatic filariasis (elephantiasis) - the first-ever USAID grant for
neglected tropical disease research and development (R&D)."
5) Articles from NRDD in 2014 making claim that pharma R&D productivity is
"on the comeback trail"
and that precompetitive research is important
and the state of UK academic drug discovery
and article on the proposed Human Vaccines Project
a feature/retrospective of Bayer's Grants4Targets open innovation scheme
and the possible use of "delinkage" strategies in the funding of antibiotic
drug discovery R&D
and an interesting recent postmortem on the results of Bayer donating
compounds to external collaborators: "Remarkably, the interactions within
this compound-donation programme had a positive influence on the
recipient's opinion of both pharmaceutical research in general and of Bayer
in particular. "
6) Proposal to extend drug patent lifetimes by a year and reinvest funds in
e.g. the NIH
as a counterpoint there was a WashPo article on "Why patents are
innovation's worst enemy"
7) Report from the Institute of Medicine on "Sharing Clinical Trial Data:
Maximizing Benefits, Minimizing Risk"
8) Thinklab - an initiative that uses project funds to pay for
contributions to open projects, an interesting idea fraught with risks that
is worth exploring (my view)
9) A recent John Oliver piece on the practice of marketing to doctors
I'm talking at conferences in London in May that have some emphasis on OSP (
AcademiaPharma <http://academiapharma.com/> and ISNTD-d3
<http://www.isntdd3.com/>) - I mention this in case these provide
opportunities to meet up.
Best wishes everyone,
MATTHEW TODD | Associate Professor
School of Chemistry | Faculty of Science
THE UNIVERSITY OF SYDNEY
Rm 519, F11 | The University of Sydney | NSW | 2006
T +61 2 9351 2180 | F +61 2 9351 3329 | M +61 415 274104
E matthew.todd at sydney.edu.au | W
http://sydney.edu.au/science/chemistry/research/todd.html | W
This email plus any attachments to it are confidential. Any unauthorised
use is strictly prohibited. If you receive this email in error, please
delete it and any attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
More information about the opensourcepharma